Benefit of surveillance for pancreatic cancer in high-risk individuals: Outcome of long-term prospective follow-up studies from three European expert centers

Journal of Clinical Oncology

Volumn 34, Issue 17, 2016, Pages 2010-2019

  Vasen, Hans ^a   Ibrahim, Isaura ^a   Robbers, Kristin ^a   Van Mil, Anneke M ^a   Potjer, Thomas ^a   Bonsing, Bert A ^a   Bergman, Wilma ^a   Wasser, Martin ^a   Morreau, Hans ^a   De Vos Tot Nederveen Cappel, Wouter H ^b   Ponce, Carmen Guillen ^c   Carrato, Alfredo ^c   Earl, Julie ^c   Mocci, Evelina ^c   Vazquez Sequeiros, Enrique ^c   Sanjuanbenito, Alfonso ^c   Muñoz Beltran, Maria ^c   Montans, José ^c   Slater, Emily P ^d   Matthäi, Elvira ^d   Fendrich, Volker ^d   Bartsch, Detlef K ^d   Schicker, Christoph ^e   Steinkamp, Martin ^e   Figiel, Jens ^e   Klöppel, Günter ^f   Langer, Peter ^g   Esposito, Irene ^h   more..

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ISALA HOSPITAL   (Netherlands)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

^d UNIVERSITY HOSPITAL MARBURG   (Germany)

^e PHILIPPS UNIVERSITY MARBURG   (Germany)

^f TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^g Klinikum Hanau   (Germany)

^h UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; BRCA1 PROTEIN; BRCA2 PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; GAMMA GLUTAMYLTRANSFERASE; P16 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER EPIDEMIOLOGY; CANCER PROGNOSIS; COHORT ANALYSIS; EARLY CANCER DIAGNOSIS; FEMALE; FOLLOW UP; GENE MUTATION; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEUROENDOCRINE TUMOR; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; PANCREAS TUMOR; PANCREATICODUODENECTOMY; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SURVIVAL RATE; CARCINOMA, PANCREATIC DUCTAL; CLINICAL TRIAL; DIAGNOSTIC IMAGING; GENETIC PREDISPOSITION; GENETICS; MULTICENTER STUDY; MUTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREATIC NEOPLASMS; PATHOLOGY; RISK FACTOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PANCREATIC DUCTAL; CYCLIN-DEPENDENT KINASE INHIBITOR P16; EARLY DETECTION OF CANCER; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; MUTATION; PANCREATIC NEOPLASMS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84971659586     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.64.0730     Document Type: Article

References (30)

1. Siegel RL, Miller KD, Jemal A: Cancer statistics, 2015. CA Cancer J Clin 65:5-29, 2015
2. Shi C, Hruban RH, Klein AP: Familial pancreatic cancer. Arch Pathol Lab Med 133:365-374, 2009
3. Bartsch DK, Gress TM, Langer P: Familial pancreatic cancer: Current knowledge. Nat Rev Gastroenterol Hepatol 9:445-453, 2012
4. de Snoo FA, Bishop DT, Bergman W, et al: Increased risk of cancer other than melanoma in CDKN2A founder mutation (p16-Leiden)-positive melanoma families. Clin Cancer Res 14:7151-7157, 2008
5. van Lier MG, Wagner A, Mathus-Vliegen EM, et al: High cancer risk in Peutz-Jeghers syndrome: A systematic review and surveillance recommendations. Am J Gastroenterol 105:1258-1264, 2010
6. Vasen HF, Gruis NA, Frants RR, et al: Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int J Cancer 87:809-811, 2000
7. van Asperen CJ, Brohet RM, Meijers-Heijboer EJ, et al: Cancer risks in BRCA2 families: Estimates for sites other than breast and ovary. J Med Genet 42:711-719, 2005
8. Wilson JMG, Jungner G: Principles and Practice of Screening for Disease. Geneva, Switzerland, World Health Organization, 1968
9. Potjer TP, Schot I, Langer P, et al: Variation in precursor lesions of pancreatic cancer among highrisk groups. Clin Cancer Res 19:442-449, 2013
10. Al-Sukhni W, Borgida A, Rothenmund H, et al: Screening for pancreatic cancer in a high-risk cohort: An eight-year experience. J Gastrointest Surg 16: 771-783, 2012
11. Canto MI, Goggins M, Yeo CJ, et al: Screening for pancreatic neoplasia in high-risk individuals: An EUS-based approach. Clin Gastroenterol Hepatol 2: 606-621, 2004
12. Canto MI, Goggins M, Hruban RH, et al: Screening for early pancreatic neoplasia in high-risk individuals: A prospective controlled study. Clin Gastroenterol Hepatol 4:766-781, 2006
13. Harinck F, Konings IC, Kluijt I, et al: A multicentre comparative prospective blinded analysis of EUS and MRI for screening of pancreatic cancer in high-risk individuals. Gut pii:gutjnl-2014-308008, 2015
14. Langer P, Kann PH, Fendrich V, et al: Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer. Gut 58: 1410-1418, 2009
15. Harinck F, Nagtegaal T, Kluijt I, et al: Feasibility of a pancreatic cancer surveillance program from a psychological point of view. Genet Med 13: 1015-1024, 2011
16. Brentnall TA: Pancreatic cancer surveillance: Learning as we go. Am J Gastroenterol 106:955-956, 2011
17. Canto MI, Hruban RH, Fishman EK, et al: Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology 142: 796-804, 2012
18. Del Chiaro M, Verbeke CS, Kartalis N, et al: Short-term results of a magnetic resonance imaging-based Swedish screening program for individuals at risk for pancreatic cancer. JAMA Surg 150:512-518, 2015
19. Kimmey MB, Bronner MP, Byrd DR, et al: Screening and surveillance for hereditary pancreatic cancer. Gastrointest Endosc 56:S82-S86, 2002 (suppl 4)
20. Poley JW, Kluijt I, Gouma DJ, et al: The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer. Am J Gastroenterol 104:2175-2181, 2009
21. Verna EC, Hwang C, Stevens PD, et al: Pancreatic cancer screening in a prospective cohort of high-risk patients: A comprehensive strategy of imaging and genetics. Clin Cancer Res 16:5028-5037, 2010
22. Schneider R, Slater EP, Sina M, et al: German national case collection for familial pancreatic cancer (FaPaCa): Ten years experience. Fam Cancer 10: 323-330, 2011
23. Vasen HF, Wasser M, van Mil A, et al: Magnetic resonance imaging surveillance detects early-stage pancreatic cancer in carriers of a p16-Leiden mutation. Gastroenterology 140:850-856, 2011
24. Bartsch DK, Sina-Frey M, Ziegler A, et al: Update of familial pancreatic cancer in Germany. Pancreatology 1:510-516, 2001
25. Mocci E, Guillen-Ponce C, Earl J, et al: PanGen-Fam: Spanish registry of hereditary pancreatic cancer. Eur J Cancer 51:1911-1917, 2015
26. Potjer TP, Bartsch DK, Slater EP, et al: Limited resection of pancreatic cancer in high-risk patients can result in a second primary. Gut 64:1342-1344, 2015
27. Aichler M, Seiler C, Tost M, et al: Origin of pancreatic ductal adenocarcinoma from atypical flat lesions: A comparative study in transgenic mice and human tissues. J Pathol 226:723-734, 2012
28. Integraal Kankercentrum Nederland: Dutch Cancer Registry. www.cijfersoverkanker.nl
29. Canto MI, Harinck F, Hruban RH, et al: International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut 62:339-347, 2013
30. Kozuka S, Sassa R, Taki T, et al: Relation of pancreatic duct hyperplasia to carcinoma. Cancer 43: 1418-1428, 1979